Archive | Redefining Early Stage Investments RSS feed for this section

RESI NYC 2018 Innovation Challenge – Check Out the Winners

8 Nov

By Karen Deyo, Investor Research Analyst, LSN

This past Monday, November 5th, at RESI NYC, all attendees, including scientist-entrepreneurs, investors and service providers, walked through the exhibit hall at the Midtown Hilton where the Innovation Challenge was taking place. The 30 finalists participating displayed their technologies, spanning from therapeutics to medical devices, diagnostics and digital health. These finalists were selected based on how investable they are, with criteria evaluating both innovation and commercial viability. We wish success to all of the finalists, but we offer congratulations to the 3 winning companies.

First Prize: Promaxo

Promaxo is a medical technology company that develops and commercializes office-based modular MRI and MRI based technologies. The Company is currently focused on advancing the solutions for prostate disease management and other urology and pelvic conditions.

Lucy Parkinson, VP of Investor Research, Life Science Nation | Amit Vohra, CEO & President, Promaxo | Dinesh Kumar, Chief Operations Officer, Promaxo | Dennis Ford, Founder & CEO, Life Science Nation

Second Prize: Keriton

Keriton Kare is a NICU feeding management, lactation analytics and patient engagement platform with end-to-end automation to improve process efficiency, reduce risk of erroneous feeds and enhance breastfeeding outcomes through a suite of mobile applications – Kare Mom and Kare Nurse.

Lucy Parkinson, VP of Investor Research, Life Science Nation | Rich Mager, CEO, Keriton | Dennis Ford, Founder & CEO, Life Science Nation

Third Prize: Thermaquil

Thermaquil discovered a completely new way of managing pain. We are first addressing the heart of the opioid crisis by treating post-surgical pain. Our minimally invasive device will be inserted at the time of surgery by the surgeon or anesthesiologist and later pulled out by the patient’s physician when recovery is complete. Thermaquil’s system creates a virtual filter across any nerve that allows patients to dial-in 0-100% how much of the nerve’s firing gets through by gently warming and cooling a short section of the nerve. Reversible thermal nerve blocks are a new mechanism of pain treatment distinct from drugs and electric stimulation. Thermaquil seeks to reduce or eliminate the need for opioids through non-addictive thermal nerve blocks.

Lucy Parkinson, VP of Investor Research, Life Science Nation | Stephen Popielarski, CEO & Co-founder, Thermaquil | Dennis Ford, Founder & CEO, Life Science Nation

RESI NYC 2018 Program Guide Is Released

1 Nov

By Nono Hu, Director of Marketing, LSN

We are counting down the days to the RESI NYC 2018 event on November 5th, and it’s now time for LSN to present the RESI NYC 2018 Program Guide. This RESI event draws upon both the rising biotech ecosystem in NY & NJ area and also LSN’s global network of investors and strategic movers in the life science space, and in the Program Guide, you can find speakers, sponsors, and innovators from all over the world. To check out the full RESI NYC 2018 content and lineup, view the Program Guide below.

Introducing the Tech Hub Pitch Challenge Finalists

25 Oct

By Karen Deyo, Investor Research Analyst, LSN

With RESI NYC just around the corner, we at LSN are excited to announce the finalists for the Tech Hub Pitch Challenge. These 8 companies, constituents of Tech Hubs located in New York and the surrounding states, have been selected to pitch to a panel of investors. Each company will have 5 minutes to pitch followed by a Q&A session including feedback from the investors.

The Pitch Challenge will be moderated by Dennis Ford, CEO & Founder, Life Science Nation. The investor panelists are:

  • Barbara Schilberg, CEO, BioAdvance
  • Steve Saheb, Associate, Brace Pharma Capital
  • Rena Rosenberg, Partner, Robin Hood Ventures
  • Nishant Rastogi, Senior Associate, New Rhein Healthcare
  • Merom Klein, Entrepreneur Mentor, Keiretsu Forum

Make sure to attend the Pitch Challenge, starting at 1:00 PM and featuring the following companies.

A2A Pharmaceuticals (JLABS NYC)

A2A Pharmaceuticals Inc. is a biotechnology company committed to the advancement of innovative therapeutic agents to treat life-threatening diseases with high unmet need and inadequate treatment options, including cancer, bacterial infections, and muscular dystrophy, among others.

Our SCULPT platform radically accelerates lead drug discovery and optimization through a systematic fragment-based drug design approach that leverages AI and deep learning to design pre-optimized molecules, highly selective to their target and with drug-like properties incorporated, reducing the time and cost of drug development.


Bright Cloud International Group (Entrepreneur’s University)

Bright Cloud International has developed, patented and tested technology that increases independence for individuals with dementia or stroke. For example, we made someone who had no longer been able to read for years, do it again in only three weeks. Current health care does not focus on the arms of stroke survivors and medication does not really work for dementia. Our proprietary adaptable and intensive gamification technology addresses these needs for improved rehabilitation and cognitive care. At clinic or at home. We would like to discuss our funding needs in a follow-up meeting.


CaroGen Corporation (UConn TIP)

CaroGen is developing transformative immunotherapies for infectious diseases and cancer, initially focusing on a cure for chronic Hepatitis B Virus (HBV). CaroGen’s virus-like-vesicle (VLV) platform was licensed from Yale. Our lead asset (CARG-101) has shown efficacy in a chronic HBV animal model. We have selected a clinical candidate, discussed our development plan with the FDA and are seeking investment opportunities or corporate partnership to allow us to conduct IND enabling studies, file an IND, and advance our HBV product to the clinic by the 3Q2019.


Corfigo (Entrepreneur’s University)

Corfigo Inc. is an early stage medical device company est. Delaware 2015. We are developing the HeArTPAD Cryo-Ablation System that treats cardiac arrhythmias for patients suffering from persistent Atrial Fibrillation. It utilizes a video-guided surgical approach (sub-xiphoid or laparoscopic/trans-diaphragmatic) to ablate the posterior wall of the left atrium and can be used concomitantly with an EP catheter ablation. The HeArTPAD and its video enabled cannula are disposable devices intended for use in cardiac ablation from an epicardial (outer surface of the heart) location. The HeArTPAD has an insulating chamber to simultaneously protect adjacent structures from unintentional ablation injury. Designed for minimally invasive ablation, our proprietary technology utilizes potent cryothermy energy coupled with sophisticated sensor technology.


Digitouch Health (BioInc)

Digitouch Health will empower anyone to measure their blood pressure with clinical-grade accuracy just by pushing a button. Upon achieving FDA clearance, Digitouch will enable billions of people to monitor hypertension much more conveniently, leading to greater awareness and control rates for hypertension, the primary risk factor for heart failure, stroke, and other cardiovascular events. Digitouch already raised $800K from the Pritzker-Vlock family. Achievement of FDA clearance should motivate smartphone and other consumer electronics manufacturers to license this technology and build it into their devices. Digitouch will also build and market standalone systems, including a medical tricorder. The potential exit valuation is >$500 million with several intermediate exit opportunities.


Grektek Holdings, Inc (NJIT)

Grektek has created everbeat, a wearable medical device that continuously and comprehensively monitors patients who have been diagnosed with, or who are at risk for, atrial fibrillation. The everbeat system is different from the competition because it works with both Apple and Android smartphones, integrates an optical sensor for active background monitoring and a clinical-grade ECG for more precise assessment, and tracks sleep, steps, medication and more through a simple-to-use watchband.

Designed by cardiologists, we are focused on helping physicians leverage everbeat to improve both their patient outcomes and their bottom line.


Raadysan Biotech, Inc. (BioInc)

We are a clinical stage biotech company and we are developing the first targeted therapy for Triple Negative Breast Cancer (TNBC).

Currently, there are no targeted therapies available in the market for the treatment of TNBC, which is the most aggressive type of breast cancer with poor survival rates. We have found a unique solution for this unmet problem by identifying a novel biomarker for TNBC, which also functions as an excellent drug target. We have developed revolutionary therapies that specifically inhibit this drug target and believe our therapies will be effective against all kinds of breast cancers.

We intend to license these therapies to pharmaceutical companies, following Phase 1a/b clinical trials and anticipate a market of about $18.2 billion.


Sonostics, Inc (Entrepreneur’s University)

Sonostics develops pacemakers for our “second hearts.” The soleus muscles in the calf of the legs are responsible for returning the blood, which collects into the lower limbs due to the influence of gravity, back to the heart, and so these muscles are commonly called our “second hearts.” About 50% of adult Americans have second heart insufficiency resulting in reduced cardiac output and numerous associated health complications (e.g. venous hypertension, chronic fatigue, hypotension and cognitive dsyfunction). Sonostics has developed, and is currently marketing, the HeartPartner, a non-invasive device which retrains the soleus muscles and reverses the complications of second heart failure. A second generation, portable technology, is under development.


%d bloggers like this: